Search - tctmd.com

Displaying 361 - 380 of 384

Sort: Relevancy | Date

News Daily News

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Caitlin E. Cox

April 19, 2013

News Daily News

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Caitlin E. Cox

April 19, 2013

News Conference News ACC 2013

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Jason Kahn

March 11, 2013

News Daily News

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Jason Kahn

January 22, 2013

News Daily News

Una Dosis Alta de Aspirina tras una PCI Primaria aumenta las Hemorragias No observandose Beneficio Isquémico alguno

L.A. McKeown

December 19, 2012

News Daily News

High-Dose Aspirin After Primary PCI Increases Bleeding with No Ischemic Benefit

L.A. McKeown

December 19, 2012

News Daily News

Risk Factor Control Linked to Better Outcomes After Peripheral Intervention

Caitlin E. Cox

December 16, 2012

News Daily News

Meta-analysis Questions Benefit of Longer Dual Antiplatelet Therapy Post-PCI

November 28, 2012

News Daily News

Apixaban Matches Bleeding Risk of Aspirin in A-fib Patients

L.A. McKeown

October 10, 2012

News Daily News

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

September 20, 2012

News Conference News ESC 2012

WOEST: Clopidogrel Alone Works Best for PCI Patients on Oral Anticoagulants

Yael L. Maxwell

August 28, 2012

News Daily News

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

L.A. McKeown

August 09, 2012

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

News Daily News

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

L.A. McKeown

June 01, 2012

News Daily News

El Apixaban Previene el ACV en Pacientes con Fibrilación Auricular con independencia de sus Antecedentes de ACV/AIT

L.A. McKeown

March 12, 2012

News Daily News

Apixaban Prevents Stroke in A-fib Patients Irrespective of Previous Stroke/TIA

L.A. McKeown

March 12, 2012

News Daily News

Silent Cerebral Infarcts After Angiography Linked to Insufficient Platelet Inhibition

L.A. McKeown

January 12, 2012

News Daily News

Six Months Sufficient for Dual Antiplatelet Therapy

Jason Kahn

October 17, 2011

News Conference News

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

August 31, 2011

News Conference News

Long-term Antiplatelet Therapy: All Risk, No Benefit

August 30, 2011

Advertisement

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Una Dosis Alta de Aspirina tras una PCI Primaria aumenta las Hemorragias No observandose Beneficio Isquémico alguno

High-Dose Aspirin After Primary PCI Increases Bleeding with No Ischemic Benefit

Risk Factor Control Linked to Better Outcomes After Peripheral Intervention

Meta-analysis Questions Benefit of Longer Dual Antiplatelet Therapy Post-PCI

Apixaban Matches Bleeding Risk of Aspirin in A-fib Patients

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

WOEST: Clopidogrel Alone Works Best for PCI Patients on Oral Anticoagulants

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

El Apixaban Previene el ACV en Pacientes con Fibrilación Auricular con independencia de sus Antecedentes de ACV/AIT

Apixaban Prevents Stroke in A-fib Patients Irrespective of Previous Stroke/TIA

Silent Cerebral Infarcts After Angiography Linked to Insufficient Platelet Inhibition

Six Months Sufficient for Dual Antiplatelet Therapy

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

Long-term Antiplatelet Therapy: All Risk, No Benefit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content